NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
Includes Data from More than Twenty-Five Studies, Including Six Using GeoMx Digital Spatial Profiler
SEATTLE, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in understanding of immune response and cancer immunotherapy using the nCounter® and GeoMx™ platforms that will be presented at the 33nd Annual Meeting of the Society of Immunotherapy for Cancer (SITC).
“We are thrilled to see a number of high-profile abstracts that include data from our GeoMx Digital Spatial Profiler at the 2018 SITC conference,” said Brad Gray, president and chief executive officer of NanoString. “The ability to quantify high-plex protein and RNA simultaneously can be a powerful tool for identifying and validating biomarkers, especially for applications in immuno-oncology.”
More than 25 abstracts using NanoString’s nCounter platform will be presented at the SITC Annual Meeting, being held at the Walter E. Washington Convention Center in Washington, D.C., Nov. 7-11, 2018. The research being presented spans a wide breadth of applications, including biomarker development, the study of immune responsiveness and resistance, and digital pathology.
Six studies included the use of NanoString’s GeoMx Digital Spatial Profiler (DSP) platform in immuno-oncology research. These abstracts include numbers 031, P113, P131, P389, P428 and P429 that are included in the table below. DSP allows for digital quantification of protein and gene expression from discrete regions of FFPE tissue in an automated and multiplex format. DSP is expected to be commercially available with the launch of a new instrument planned for mid-2019, and is currently accessible through the company’s Technology Access Program (TAP). NanoString is currently accepting applications for the TAP for its DSP technology at TAP@Nanostring.com.
Each year, SITC recognizes publications that demonstrated excellence in scientific research with its Journal for ImmunoTherapy of Cancer (JITC) best paper awards. The 2018 JITC “Best Basic Science Paper” was awarded for “Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA),” to a team led by NanoString researchers that included, Patrick Danaher, Ph.D., Sarah Warren, Ph.D., Rongze Lu, Ph.D., Josue Samayoa, Ph.D., Amy Sullivan, B.S., Irena Pekker, Ph.D., Brett Wallden, M.S., Francesco M. Marincola, M.D., and Alessandra Cesano, M.D., Ph.D.
NanoString will host a Key Opinion Leader Dinner for Digital Spatial Profiling on the evening of Thursday, Nov. 8th. The dinner features presentations by leading academic and biopharma researchers on the use of nCounter gene expression and GeoMx Digital Spatial Profiling technologies to discover biomarkers for treating bladder cancer and melanoma.
At the 2018 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 and Data Analysis and Digital Spatial Profiling at booth #600.
Abstract # Title Presenting Author Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in O31 resectable breast cancer and head and neck David Page, MD carcinoma Providence Portland Cancer Center, Portland, OR, USA Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and O45 prolonged survival following treatment with the Lawrence Fong, MD A2AR antagonist, CPI-444 University of California, San Francisco, CA, USA Consistent pharmacodynamics and immunological P25 responses to the TLR9 agonist, SD-101, following Albert Candia, PhD intratumoral injection in multiple cancer types Dynavax Technologies, Berkeley, CA, USA Development of biomarkers to assess adenosine generation & activity in support of clinical P35 trials conducted with the adenosine receptor Daniel DiRenzo, PhD antagonist AB928 Arcus Biosciences, Hayward, CA, USA The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient P43 tumors Colt Egelston, PhD Beckman Research Institute, City of Hope, Duarte, CA, USA X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor Robert Andtbacka, MD P53 inflammatory status in the microenvironment of Huntsman Cancer Institute, Salt Lake City, UT, melanoma USA Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients P54 treated with the adenosine A2A receptor (A2AR) Andrew Hotson, PhD antagonist, CPI-444 Corvus Pharmaceuticals, Burlingame, CA, USA Innovative combinatorial approach to characterize the immune landscape and analyze the tumor P67 response after anti-PD-1 blockade in a 3D ex-vivo Melba Marie Page, PhD tumoroid system of non-small cell lung cancer Nilogen Oncosystems, Tampa, FL, USA Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody Luc R. Desnoyers, PhD P87 therapeutic antibody prodrug targeting PD-L1, in CytomX Therapeutics, Inc., South San Francisco, a phase 1/2a trial CA, USA Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid P113 leukemia Sergio Rutella, MD, PhD Nottingham Trent University, Nottingham, UK High-plex predictive marker discovery for David Rimm, MD, PhD P131 melanoma immunotherapy treated patients using Yale University School of Medicine, New Haven, NanoString® Digital Spatial Profiling CT, USA Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of P136 the VEGF receptor inhibitor axitinib plus Breelyn Wilky, MD pembrolizumab University of Miami - SCCC, Miami, FL, USA “Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune P139 checkpoint inhibitor (ICI) dually targeting Funda Meric-Bernstam, MD V-domain Ig suppressor of T-cell MD Anderson Cancer Center, Houston, USA Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker Ahmad Halwani, MD P327 activity and improved clinical outcomes in Huntsman Cancer Institute, Salt Lake City, UT, patients with follicular lymphoma USA Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to P349 tumor regression upon combined MEK and HDAC Phyllis Cheung, PhD inhibition in spontaneous PDAC mouse model University Hospital Essen, DKFZ, Essen, Germany Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in P354 Non-Small Cell Lung Cancer Pierre-Olivier Gaudreau MD Anderson Cancer Center, Houston, USA Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined P360 with anti-PD-1 antibody Qun Jiang, PhD National Institutes of Health, Bethesda, MD, USA Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency P389 ablation and ipilimumab Trieu My Van, PhD NKI/Nanostring, Amsterdam, Netherlands Spatially-resolved, high-plex digital profiling P428 enables characterization of complex immune Sarah Church, PhD biology of the colorectal cancer microenvironment NanoString Technologies, Seattle, WA, USA Integrative spatially-resolved, high-plex digital profiling enables characterization of complex P429 immune biology in the tumor microenvironment of Carmen Ballesteros Merino, PhD, Providence mesothelioma Portland Cancer Center, Portland, OR, USA The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory P450 activity and enhances immune checkpoint blockade Luis Carvajal, PhD in syngeneic mouse models Aileron Therapeutics, Inc., Cambridge, MA, USA Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous P460 ovarian cancer Sarah Nersesian, MSc Queen’s University, Kingston, ON, Canada Transcriptomic profiles conducive to P468 immune-mediated tumor rejection in human breast Mariya Rozenblit, MD cancer skin metastases treated with Imiquimod Yale University, Connecticut, CT, USA Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated P564 enterocolitis Daniel Johnson, MD MD Anderson Cancer Center, Houston, TX, USA Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and P597 BTLA Nicola Annels, PhD The University of Surrey, Guildford, UK Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell P614 death and induces innate and adaptive immune Amanda McDaniel, BA responses Pulse Biosciences, Burlingame, CA, USA Selective CD47 immune checkpoint targeting on P650 tumor cells modulates the tumor microenvironment Vanessa Buatois, PhD to enhance macrophage tumoricidal function Novimmune SA, Geneva, Switzerland
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company’s current and future products and the timing of future product launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
NanoString, NanoString Technologies, the NanoString logo, GeoMx DSP, 3D Biology, 3D Flow, nCounter, PanCancer IO360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Doug FarrellVice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768